Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Efficacy and safety of adalimumab in ankylosing spondylitis or psoriatic arthritis with a history of anti-TNF therapy

Two 12-week open-label studies of adalimumab (with an optional 20-week extension) were conducted in 1,692 patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA). They had previously been unsuccessfully treated with etanercept, infliximab, both, or had no previous antitumor necrosis factor (TNF) therapy. Efficacy at 12 weeks of adalimumab treatment in AS patients was assessed by a 40%improvement in the Assessment of SpondyloArthritis International Society criteria (ASA40) and a 50% or greater improvement in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50). The PsA patients were assessed by the modified Psoriatic Arthritis Response Criteria (mPsARC) and a 50% or greater improvement in the American College of Rheumatology response criteria (ACR50). In ...